Crypto Market Cap, BTC/USD, ETH/USD, USDT/USD, XRP/USD, Bitcoin
LAND SECURITIES GROUP PLC ORD 10 2/3P, BURFORD CAPITAL LIMITED ORD NPV (DI), SMITH & NEPHEW PLC ORD USD0.20, BIDSTACK GROUP PLC ORD 0.5P, LLOYDS BANKING GROUP PLC ORD 10P, BARCLAYS PLC ORD 25P
FTSE 100, DAX Index, Euro Stoxx 50, S&P 500, Nasdaq Composite, Nikkei 225
US 10Y, Euro Bund, Germany 10Y, Japan 10Y Yield, UK 10Y, India 10Y
Support 4900. Long term prospek sebab vaccine player. Distribute vaccine Sinovac. Cl below 4000.
Pre market price at 98.9 is above 95 resistance after covid-19 vaccine test results. Also all time high, which makes it bullish
Will MRNA break 86.7 based on it's Covid-19 vaccine work? NOTE: Although not a recommendation, if you like my work, please donate a few coins. Thanks.
Will Hikma break out after a 5 year H&S pattern, now that it's making progress in the Covid-19 vaccine business?
Pressure is building and a breakout could be imminent. It's taken 6 years from May 2013 where the high was 1816 Needs substantive news to make the push over the 1750s
MNK is dead or almost dead. Often times there is a dead cat bounce in stocks like these, as 'everybody' gets the same idea to throw some money at it. This is a high risk scenario but with potentially good risk to reward ratios. Disclaimers : I've clearly said this is high risk. This not advice to trade in securities. I am simply showing what may happen from...
SELL – GLAXOSMITHKLINE (GSK) GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. Fundamentals...
Last post: June 3rd. See chart . Review: Price was approaching the resistance level. Update: Since the last post, price broke above the resistance level but has failed to stay there and has now fallen back below that level. The breakout was a fake breakout. Conclusion: We need price to break the resistance level again and stay above it before looking for...
Last post: Feb 28th. See chart . Review: Price had broken a resistance level with a strong move to the upside. Update: Price continued to trend higher but is now in a period of consolidation. Conclusion: We will be waiting for a breakout of the resistance of the consolidation zone before considering a trade. Any comments or questions, do not hesitate to...
Prudent Drug Discovery Company Low market cap ( appox £13m at time of writing ). Issues shares very rarely ( last placing nearly four years ago ). Has material interest in its work from larger partners ( Pharmaxis ). Sold interest in LOXL2 programme for £5m to Pharmaxis in December. Pharmaxis continues to fund and develop LOXL2 inhibitors and Synairgen retains...